5 Einträge gefunden

1. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

   1. Blauvelt, Andrew
   2. Langley, Richard G
   3. Lacour, Jean-Philippe
   4. Toth, Darryl
   5. Laquer, Vivian
   6. Beissert, Stefan
   7. Wollenberg, Andreas

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

   1. Blauvelt, Andrew
   2. Armstrong, April W
   3. Langley, Richard G
   4. Gebauer, Kurt
   5. Thaçi, Diamant
   6. Bagel, Jerry
   7. Guenther, Lyn C

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Bimekizumab versus Adalimumab in Plaque Psoriasis

   1. Warren, Richard B
   2. Blauvelt, Andrew
   3. Bagel, Jerry
   4. Papp, Kim A
   5. Yamauchi, Paul
   6. Armstrong, April
   7. Langley, Richard G

   2021 - Forschungsinformationssystem des UKE
4. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

   1. Reich, Kristian
   2. Papp, Kim A
   3. Blauvelt, Andrew
   4. Langley, Richard G
   5. Armstrong, April
   6. Warren, Richard B
   7. Gordon, Kenneth B

   2021 - Forschungsinformationssystem des UKE
5. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

   1. Reich, Kristian
   2. Armstrong, April W
   3. Langley, Richard G
   4. Flavin, Susan
   5. Randazzo, Bruce
   6. Li, Shu
   7. Hsu, Ming-Chun

   2019 - Forschungsinformationssystem des UKE